Semaglutide's H1 Revenue Hits $9.2B, Phase III Success in Heart Failure Indication

Novo Nordisk has released its H1 2023 results as scheduled, reporting a total revenue of DKK 107.667 billion (approximately USD 15.97 billion), reflecting a 29% YoY increase. The diabetes and obesity care business experienced a 36% YoY sales growth, reaching DKK 98.977 billion (USD 14.67 billion). Notably, sales of GLP-1 diabetes drugs surged by 49% YoY to DKK 54.736 billion (USD 8.11 billion), while sales of obesity drugs soared by 158% to DKK 18.148 billion (USD 2.69 billion).

?

Among the specific products, the revenue generated by semaglutide injection Ozempic, used for blood sugar reduction, increased by 58% to DKK 41.741 billion (USD 6.19 billion). Additionally, semaglutide tablet Rybelsus saw a revenue increase of 97% to DKK 8.344 billion (USD 1.24 billion), and semaglutide injection Wegovy, used for weight loss, achieved a remarkable triple growth (+367%), generating DKK 12.081 billion (USD 1.8 billion) in revenue. The combined revenue for these three products in the year's first half amounted to USD 9.22 billion, projected to surpass USD 20 billion for the entire year. Novo Nordisk's half-year report also highlighted the positive results of the Phase III STEP HFpEF study, which evaluated the efficacy of semaglutide 2.4 mg in treating heart failure patients with preserved ejection fraction (HFpEF).

?

With years of expertise in CDMO services utilizing microbial expression systems like Escherichia coli and yeast, Yaohai Bio-Pharma can produce GMP-grade recombinant peptides, including semaglutide/GLP-1 analogs. Our extensive experience in production ensures short cycle times and high product quality, enabling us to meet the requirements for product registration and support numerous biopharmaceutical companies involved in recombinant peptide research.

?

As China's first and largest biologics CRDMO specializing in microbial expression systems, Yaohai Bio-Pharma offers tailored end-to-end solutions ranging from DNA design and synthesis, microbial strain engineering and construction, to GMP or non-GMP level drug substance manufacturing, and fill & finish services for diverse modalities such as recombinant proteins, peptides, polypeptides, enzymes, single domain antibodies (sdAbs), plasmid DNA, mRNA, glyco-polymers, and VLPs. We are committed to meeting global customers' clinical and commercial needs in biological drugs, biosimilars, vaccines, and diagnostics for both human and veterinary use.

?

We are also actively seeking institutional or individual global partners with the most competitive compensation in the industry. If you have any questions, please do not hesitate to contact us: [email protected].